LigF appears to be the most promising candidate among the tested agents, since it inhibits aromatase, does not promote uterine growth, limits the protein translation machinery, resembles aromatase and CDK inhibitor signatures in ex vivo experiments using human breast samples, and reduces proliferative activity in breast cancer cell lines. The gene discussed is CYP19A1; the disease is breast carcinoma.